Literature DB >> 11480400

EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.

G T Tucker, J B Houston, S M Huang.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11480400     DOI： 10.1016/s0928-0987(01)00148-8

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN： 0928-0987            Impact factor:   4.384


× No keyword cloud information.
  7 in total

1.  Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

Authors:  Donald R Stanski; Malcolm Rowland; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

3.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

Authors:  Ashok Rakhit; Michael P Pantze; Scott Fettner; Hannah M Jones; Jean-Eric Charoin; Myriam Riek; Bert L Lum; Marta Hamilton
Journal:  Eur J Clin Pharmacol       Date:  2007-11-14       Impact factor: 2.953

Review 4.  Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.

Authors:  Stéphane Mouly; Christophe Meune; Jean-François Bergmann
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

5.  Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.

Authors:  Sonja Krösser; Roland Neugebauer; Hugues Dolgos; Markus Fluck; Karl-Ludwig Rost; Andreas Kovar
Journal:  Eur J Clin Pharmacol       Date:  2006-03-07       Impact factor: 2.953

6.  Isolation, analysis and in vitro assessment of CYP3A4 inhibition by methylxanthines extracted from Pu-erh and Bancha tea leaves.

Authors:  Kaloyan D Georgiev; Maya Radeva-Ilieva; Stanila Stoeva; Iliya Zhelev
Journal:  Sci Rep       Date:  2019-09-26       Impact factor: 4.379

7.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.